Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05696769 · ClinicalTrials.gov registry record
Tourette Discrimination (TD) Stigma Scale
A clinical trial of Tourette Syndrome and Tourette Syndrome in Adolescence, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 43
- Enrollment target
- 1
- Study location
NCT05696769: Completed study of Tourette Syndrome and Tourette Syndrome in Adolescence, sponsored by Wake Forest University Health Sciences.
NCT05696769 is a study of Tourette Syndrome and Tourette Syndrome in Adolescence that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 43 participants, below the 85-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05696769, a study of Tourette Syndrome and Tourette Syndrome in Adolescence, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this qualitative study is to understand the challenges of stigmatization and discrimination in children and young adults with Chronic Tic Disorders (CTD), including Tourette Syndrome. Measuring and understanding how stigma affects those with CTD will help inform future work.
Primary Outcome
Confirmatory factor analysis will be used to assess the factor structure of the hypothesized domains. Mean TD-STIGMA scores will be calculated. Internal consistency (both overall and within each domain) will be evaluated using Cronbach's alpha. Intraclass correlation will be used to evaluate test-retest reliability by retesting a subset of participants (n=20) two weeks after test administration. Some items may be removed from the list based on the results of the factor analysis, internal consist
Conditions Studied
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2023-03-04 |
| Est. Completion | 2024-06-27 |
What the finished NCT05696769 record still lists
NCT05696769 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 85-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (49% lower).
The record links to 5 conditions, with Tourette Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT05696769 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05696769 about?
NCT05696769 is a clinical study titled "Tourette Discrimination (TD) Stigma Scale". The goal of this qualitative study is to understand the challenges of stigmatization and discrimination in children and young adults with Chronic Tic Disorders (CTD), including Tourette Syndrome. Measuring and understanding how stigma affects those with CTD will help inform future work.
What is the current status of trial NCT05696769?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2023-03-04. Estimated completion is 2024-06-27.
What conditions does trial NCT05696769 study?
This clinical trial studies the following conditions: Tourette Syndrome, Tourette Syndrome in Adolescence, Tics, Tourette Syndrome in Children, Tic Disorder, Childhood.
Who is sponsoring clinical trial NCT05696769?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05696769 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tourette Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05696769's enrollment target sits among peer trials
43 19th of 33 higher than 15 of 33 other Tourette Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tourette Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
RECRUITING
-
Remote Delivery of a Mindfulness-based Intervention for Tics
RECRUITING · NA
-
Sensory Symptoms in Tourette Syndrome
RECRUITING
-
Multimodal Profiling of Response to Pediatric Comprehensive Behavioral Intervention for Tics
RECRUITING · Phase 2
-
Trajectories of Change in Tourette Syndrome
RECRUITING · NA
-
Longitudinal Impact of Stressors in Adults With Tourette Syndrome
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI